News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Eli Lilly and Company Tops Forecast On Cost Cuts, Sales Fall Short
October 21, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- Eli Lilly & Co.'s third-quarter earnings rose 38% as the company rebounded from a year-earlier quarter hamstrung by $549.8 million of charges as revenue edged higher.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Eli Lilly and Company
MORE ON THIS TOPIC
Funding
China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill
January 23, 2026
·
1 min read
·
Tristan Manalac
Vaccines
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg
January 23, 2026
·
2 min read
·
Tristan Manalac
Cancer
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments
January 22, 2026
·
2 min read
·
Tristan Manalac
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
January 22, 2026
·
1 min read
·
Jennifer Smith-Parker
